Sionna Therapeutics, Inc.
Business
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule CFTR modulators to treat cystic fibrosis, with a focus on NBD1 stabilizers that address the F508del mutation affecting most CF patients. The company's pipeline includes SION-719 and SION-451 (NBD1 stabilizers) in Phase 2a and Phase 1 trials respectively, alongside complementary modulators designed for combination therapies. Sionna intends to commercialize approved products independently in the U.S. and selected international markets through a specialized sales force targeting CF treatment centers.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development | 60 | 57 | |
| General and administrative | 29 | 13 | |
| Total operating expenses | 89 | 71 | |
| Loss from operations | −89 | −71 | |
| Interest income | 13 | 8 | |
| Other income | 419,000 | 698,000 | |
| Total other income | 14 | 9 | |
| Net loss | −75 | −62 | |
| Net loss per share, basic (in dollars per share) | −1.88 | −15.99 | |
| Net loss per share, diluted (in dollars per share) | −1.88 | −15.99 | |
| Weighted-average common shares outstanding, basic (in shares) | 40 | 4 | |
| Weighted-average common shares outstanding, diluted (in shares) | 40 | 4 | |
| Unrealized gain on marketable securities | 172,000 | 368,000 | |
| Total other comprehensive gain | 172,000 | 368,000 | |
| Comprehensive loss | −75 | −61 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-05-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 58 | 38 | — | — | |
| Marketable securities, current | 177 | 110 | — | — | |
| Prepaid expenses and other current assets | 6 | 3 | — | — | |
| Total current assets | 241 | 151 | — | — | |
| Property and equipment, net | 2 | 2 | — | — | |
| Marketable securities, noncurrent | 74 | 21 | — | — | |
| Restricted cash | 963,000 | 962,000 | — | — | |
| Operating lease right-of-use asset | 7 | 8 | — | 10 | |
| Other assets | 0 | 3 | — | — | |
| Total assets | 326 | 186 | — | — | |
| Accounts payable | 769,000 | 1 | — | — | |
| Accrued expenses | 10 | 8 | — | — | |
| Operating lease liability, current | 1 | 1 | — | — | |
| Other current liabilities | 6,000 | 0 | — | — | |
| Total current liabilities | 12 | 10 | — | — | |
| Operating lease liability, noncurrent | 7 | 9 | — | — | |
| Total liabilities | 19 | 19 | — | — | |
| Commitments and contingencies (Note 8) | — | — | — | — | |
| Convertible preferred stock, value | 0 | 330 | — | — | |
| Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | |
| Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 44,723,585 and 4,798,721 shares issued, 44,723,585 and 4,722,763 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 45,000 | 5,000 | — | — | |
| Additional paid-in capital | 563 | 17 | — | — | |
| Accumulated other comprehensive income | 540,000 | 368,000 | — | — | |
| Accumulated deficit | −256 | −181 | — | — | |
| Total stockholders equity (deficit) | 307 | −164 | −115 | — | |
| Total liabilities, convertible preferred stock and stockholders equity (deficit) | 326 | 186 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Stock-based compensation expense | 12 | 4 | |
| Non-cash operating lease expense | 2 | 2 | |
| Amortization of discount on marketable securities | −3 | −3 | |
| Non-cash expense related to IPR&D acquisition | 0 | 9 | |
| Depreciation expense | 600,000 | 700,000 | |
| Prepaid expenses and other current assets | −2 | −3 | |
| Accounts payable | −417,000 | 467,000 | |
| Accrued expenses and other current liabilities | 2 | 1 | |
| Operating lease liability | −2 | −2 | |
| Other assets | 0 | 35,000 | |
| Net cash used in operating activities | −66 | −53 | |
| Purchases of property and equipment | −377,000 | −27,000 | |
| Purchases of marketable securities | −325 | −183 | |
| Maturities of marketable securities | 207 | 56 | |
| Net cash used in investing activities | −119 | −127 | |
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | 202 | 0 | |
| Proceeds from issuance of Series C convertible preferred stock, net of issuance costs | 0 | 181 | |
| Payment of deferred offering costs | 0 | −3 | |
| Exercise of common stock options | 4 | 141,000 | |
| Net cash provided by financing activities | 206 | 179 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 21 | −733,000 | |
| Conversion of convertible preferred stock into common stock upon closing of initial public offering | 330 | 0 | |
| Offering costs transferred to additional paid in capital | 4 | 0 | |
| Deferred offering costs in accrued expenses | 0 | 492,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Sionna Therapeutics, Inc.'s CIK number?
Sionna Therapeutics, Inc.'s SEC CIK number is 0002036042 (2036042). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Sionna Therapeutics, Inc.'s SEC filings?
All of Sionna Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Sionna Therapeutics, Inc. last report earnings?
Sionna Therapeutics, Inc. (SION) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-033870). This is Sionna Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Sionna Therapeutics, Inc.'s most recent earnings 8-K?
Sionna Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001628280-26-033870. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Sionna Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →